Versant's plans

Versant Ventures says it will not alter its plans to invest evenly between therapeutics and medical device companies, even though it is left with only two active therapeutics-focused managing directors - Samuel Colella and Bradley Bolzon - after four of the firm's 13 managing directors decided they would not make new investments from the firm's next fund.